GlassScriptPhysician profile
William D Astin
NPI 1356310759
$8,498.37
in general payments reported to CMS, 2019-2025
38 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $1,519 · 2021: $2,085 · 2022: $1,293 · 2023: $781 · 2024: $602 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,652.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $945.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $808.39 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $592.44 | 2019-2025 | Synthroid, Ubrelvy |
| Glaxosmithkline, LLC. | $504.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $489.51 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.08 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $394.39 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $375.18 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $304.83 | 2020-2023 | Nexletol |
| Amgen INC. | $246.70 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.22 | 2019-2022 | |
| Amarin Pharma, INC. | $208.47 | 2019-2021 | |
| Pfizer INC. | $167.91 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.33 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Astin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.